Clinical trials: Giant Cell Glioblastoma
Brain and Central Nervous System Tumors
Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT01013285
- Testing
- bevacizumab, temozolomide, external beam radiation therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Radiation Therapy in Treating Patients With Glioblastoma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as pentoxifylline and hydroxyurea may make tumor cells more sensitive to radiation therapy.
- Trial name
- NCT00019058
- Testing
- chemotherapy, hydroxyurea, pentoxifylline
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also make tumor cells more sensitive to radiation therapy. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00869401
- Testing
- dasatinib, temozolomide, radiation therapy
- Where
- 207 sites in United States
- Volunteers
- 217 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00014170
- Testing
- gefitinib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma
RATIONALE: IL-4(38-37)-PE38KDEL immunotoxin may locate tumor cells and kill them without harming normal cells. This may be an effective treatment for recurrent malignant astrocytoma.
- Trial name
- NCT00003842
- Testing
- interleukin-4 PE38KDEL cytotoxin, isolated perfusion, surgical procedure
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Barrett Cancer Center
Brain and Central Nervous System Tumors
Acridine Carboxamide in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of acridine carboxamide in treating patients who have…
- Trial name
- NCT00004937
- Testing
- acridine carboxamide
- Where
- United Kingdom
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of erlotinib in treating patients with…
- Trial name
- NCT00227032
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00006263
- Testing
- filgrastim, carboplatin, temozolomide
- Where
- United States
- Sponsor
- NYU Langone Health
Brain and Central Nervous System Tumors
Procarbazine in Treating Patients With Recurrent Brain Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of procarbazine in treating patients who have…
- Trial name
- NCT00004004
- Testing
- procarbazine hydrochloride
- Where
- 10 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Brain and Central Nervous System Tumors
Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for patients with glioma.
- Trial name
- NCT00003916
- Testing
- radiation therapy, stereotactic radiosurgery
- Where
- 8 sites in Australia, France and 5 more
- Volunteers
- 25 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors
Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005855
- Testing
- carmustine, efaproxiral
- Where
- 9 sites in United States
- Volunteers
- 48 people
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
This phase I/II trial is studying the side effects and best dose of oxaliplatin in treating patients with newly diagnosed glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00005856
- Testing
- oxaliplatin, pharmacological study
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of irofulven in treating patients who have progressive…
- Trial name
- NCT00012038
- Testing
- irofulven
- Where
- 10 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
RATIONALE: Bafetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial studies bafetinib in treating patients with recurrent high-grade glioma or brain…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma
- Trial name
- NCT01234740
- Testing
- bafetinib, microdialysis, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
This phase I/II trial studies the side effects and best dose of gefitinib when given together with radiation therapy and to see how well it works in treating patients with glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00052208
- Testing
- gefitinib, radiation therapy, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma
RATIONALE: ATN-161 may stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or…
- Trial name
- NCT00352313
- Testing
- ATN-161, carboplatin
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Adult Giant Cell Glioblastoma, Adult Glioblastoma
AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme
This phase II trial is studying how well AZD2171 works in treating patients with recurrent glioblastoma multiforme. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00305656
- Testing
- cediranib maleate
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
MRI in Evaluating the Effect of Efaproxiral on the Brain in Patients With Recurrent or Progressive Glioma Enrolled on Clinical Trial NABTT-9806
RATIONALE: Diagnostic procedures, such as MRI, may help doctors learn how efaproxiral works in the brain and help plan the best treatment.
- Trial name
- NCT00433472
- Testing
- magnetic resonance imaging (MRI)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain and Central Nervous System Tumors
Vaccine Therapy in Treating Patients With Malignant Glioma
RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00068510
- Testing
- therapeutic autologous dendritic cells
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Boron Neutron Capture Therapy Following Surgery in Treating Patients With Glioblastoma Multiforme Removed During Surgery
RATIONALE: Boron neutron capture therapy may selectively kill tumor cells without harming normal tissue. PURPOSE: This phase I trial is studying the side effects and best dose of boron neutron capture therapy following surgery in…
- Trial name
- NCT00004015
- Testing
- sodium borocaptate, adjuvant therapy
- Where
- 8 sites in Austria, Canada and 4 more
- Volunteers
- 36 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC